PBRM1 and BAP1: novel genetic mutations in malignant transformation of craniopharyngioma-a case report

被引:1
|
作者
Tamura, Mitsuru [1 ]
Yokogami, Kiyotaka [1 ]
Watanabe, Takashi [1 ]
Kawano, Tomoki [1 ]
Muta, Junichiro [1 ]
Yamashita, Shinji [1 ]
Oguri, Nobuyuki [2 ]
Sato, Yuichiro [2 ]
Takeshima, Hideo [1 ]
机构
[1] Univ Miyazaki, Fac Med, Dept Neurosurg, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan
[2] Univ Miyazaki, Univ Miyazaki Hosp, Dept Diagnost Pathol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan
关键词
Craniopharyngioma; Malignant transformation; BAP1; PBRM1; RENAL-CELL CARCINOMA;
D O I
10.1007/s10014-022-00444-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant craniopharyngioma is especially rare, so the causes and genetic mutations associated with the malignant transformation have not been explained in detail. We investigated the molecular genetic characteristics of malignant transformation in craniopharyngioma. A 53-year-old man with a history of adamantinomatous craniopharyngioma presented with complaints of subcutaneous swelling. Magnetic resonance imaging showed a less enhanced intradural supra-sellar lesion and a heterogeneously well-enhanced extradural invasive lesion infiltrating the dura mater, brain, frontal bone, and subcutaneous tissue. Histopathological examination of the recurrent tumor revealed typical findings of both craniopharyngioma (intradural supra-sellar lesion) and malignant transformation, such as marked nuclear atypia with mitosis (invasive extradural lesion), which were not present in the primary tumor. A genetic panel test with the Oncopanel system was performed to investigate the genetic mutations responsible for the malignant transformation. Four genetic mutations were identified: CTNNB1 c.C98T, TP53 p.C135fs*35(PLS = 3 UPD/LOH), PBRM1 p.R1000*(PLS = 3 UPD/LOH), and BAP1 p.L650fs*5(PLS = 3 UPD/LOH). Sanger sequencing showed CTNNB1 in both the intradural supra-sellar and extradural invasive lesions, but TP53, PBRM1, and BAP1 only in the extradural invasive lesion. The genetic mutations of PBRM1 and BAP1 may be genetic factors in the malignant transformation of adamantinomatous craniopharyngioma.
引用
收藏
页码:40 / 44
页数:5
相关论文
共 50 条
  • [31] Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond
    Pagliuca, F.
    Marino, F. Zito
    Morgillo, F.
    Della Corte, C.
    Santini, M.
    Vicidomini, G.
    Guggino, G.
    De Dominicis, G.
    Campione, S.
    Accardo, M.
    Cozzolino, I
    Franco, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (12) : 4236 - 4246
  • [32] Differential overall survival (OS) results in RECORD-3 study based on three distinct mRCC molecular subgroups classified by BAP1 and/or PBRM1 mutations.
    Hsieh, James
    Chen, David
    Wang, Patricia
    Chen, Yingbei
    Marker, Mahtab
    Patel, Parul
    Chevinsky, Michael
    Bhanot, Umesh
    Pinciroli, Patrizia
    Berger, Michael F.
    Cheng, Emily
    Lee, William
    Knox, Jennifer J.
    Voss, Martin Henner
    Voi, Maurizio
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [33] SF3B1 and BAP1 Mutations in malignant blue Nevus
    Griewank, K.
    Mueller, H.
    Jackett, L.
    Emberger, M.
    Moeller, I
    van de Nes, J.
    Zimmer, L.
    Livingstone, E.
    Wiesner, T.
    Scholz, S.
    Cosgarea, I
    Sucker, A.
    Schimming, T.
    Hillen, U.
    Schilling, B.
    Paschen, A.
    Reis, H.
    Mentzel, T.
    Kutzner, H.
    Ruetten, A.
    Murali, R.
    Scolyer, R.
    Schadendorf, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 2 - 2
  • [34] Functional role of SETD2, BAP1, PARP-3 and PBRM1 candidate genes on the regulation of hTERT gene expression
    Linne, Hannah
    Yasaei, Hemad
    Marriott, Alison
    Harvey, Amanda
    Mokbel, Kefah
    Newbold, Robert
    Roberts, Terry
    ONCOTARGET, 2017, 8 (37) : 61890 - 61900
  • [35] Concomitant Loss of PBRM1 and BAP1 Protein Expression is an Important Prognostic Event in Early Stages of Clear Cell Renal Cell Carcinoma
    da Cunha, Isabela W.
    da Costa, Walter H.
    Fares, Aline F.
    Bezerra, Stephania M.
    Schultz, Luciana
    Guimaraes, Gustavo C.
    Zequi, Stenio C.
    LABORATORY INVESTIGATION, 2018, 98 : 336 - 336
  • [36] Loss of BAP1 and PBRM1 protein expression and its association with clear cell renal cell carcinoma-specific survival.
    Joseph, Richard Wayne
    Kapur, Payal
    Serie, Daniel
    Eckel-Passow, Jeanette
    Thai Huu Ho
    Brugarolas, James
    Parker, Alexander S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [37] BAP1 inactivated melanocytic tumor: a case report
    Sahin, Ugur
    Barghorn, Andre
    Kilian, Katharina
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (10): : 1231 - 1234
  • [38] Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations
    Maffeis, Valeria
    Cappellesso, Rocco
    Nicole, Lorenzo
    Guzzardo, Vincenza
    Menin, Chiara
    Elefanti, Lisa
    Schiavi, Francesca
    Guido, Maria
    Fassina, Ambrogio
    ENDOCRINE PATHOLOGY, 2019, 30 (04) : 276 - 284
  • [39] Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations
    Valeria Maffeis
    Rocco Cappellesso
    Lorenzo Nicolè
    Vincenza Guzzardo
    Chiara Menin
    Lisa Elefanti
    Francesca Schiavi
    Maria Guido
    Ambrogio Fassina
    Endocrine Pathology, 2019, 30 : 276 - 284
  • [40] Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations
    Kadariya, Yuwaraj
    Cheung, Mitchell
    Xu, Jinfei
    Pei, Jianming
    Sementino, Eleonora
    Menges, Craig W.
    Cai, Kathy Q.
    Rauscher, Frank J.
    Klein-Szanto, Andres J.
    Testa, Joseph R.
    CANCER RESEARCH, 2016, 76 (09) : 2836 - 2844